A Phase II study of TAS 102 in Combination with Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
This is a single institutional phase II single arm two-stage design trial using the combination of TAS 102 and ramucirumab in advanced, refractory gastric or GEJ adenocarcinoma.
Primary Objective To determine the 6 month overall survival in patients with advanced, refractory gastric or gastroesophageal junction (GEJ) adenocarcinoma receiving TAS 102 in combination with ramucirumab. Secondary Objectives 1. To determine the frequency and severity of adverse events and tolerability of TAS 102 plus ramucirumab in patients with advanced, refractory gastric or GEJ adenocarcinoma 2. To determine the objective response rate of TAS 102 in combination with ramucirumab based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 3. To determine the progression free survival in patients with advanced, refractory gastric or GEJ adenocarcinoma receiving TAS 102 in combination with ramucirumab. Exploratory Objectives 1. To evaluate potential correlations between blood biomarkers and clinical outcome using a multiplex assay evaluating circulating angiogenic biomarkers
Chemotherapy (NOS); Immunotherapy; Therapy (NOS)
IMC-1121B (Ramucirumab); Ramucirumab (); TAS 102 ()
Back to top
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.